End of 2005 the Capsulution Nanoscience AG entered a cooperation agreement for the development of novel products in the field of medical technology. The new Capsulution’s partner is a leading and internationally renowned company in the field of medical implants. The cooperation project aims at combining Capsulution´s nana-encapsulation technology with medical products. The initial five-year project will be co-financed by the partner company with 500,000 euros during the first year.
Capsulution develops innovative solutions for pharmaceutically active compounds – so-called drug delivery systems – to transport these safely and with increased effectiveness to the desired location of action in the human body. To achieve this, Capsulution applies its worldwide-patented LBL-Technology® (layer-by-layer technology), exclusively licensed by the Max-Planck-Institute. Because of their minute dimensions, their diverse functionalities as well as their highly reproducible production the capsules are suitable for a wide range of applications.
By combining implants with drug delivery systems the cooperation focuses on increasing the therapeutic efficacy of novel medical technology products. During the production process specific nano-capsules that are filled with active compounds are applied biocompatibility of the implant. Upon implantation the capsules’ contents can be released in a time-lapsed fashion.
"On the basis of the successful developments in recent years many customers prefer to invest in long-term development cooperations with Capsulution,“ said Prof. Edwin Donath, Chairman of the Board of Supervisors of Capsulution NanoScience AG. “This allows us to provide further innovative, specialized and high-qualified products”.
For any further inquiries and information of Capsulution Nanoscience AG, please contact the mentioned contact persons.
Capsulution develops innovative solutions for pharmaceutically active compounds – so-called drug delivery systems – to transport these safely and with increased effectiveness to the desired location of action in the human body. To achieve this, Capsulution applies its worldwide-patented LBL-Technology® (layer-by-layer technology), exclusively licensed by the Max-Planck-Institute. Because of their minute dimensions, their diverse functionalities as well as their highly reproducible production the capsules are suitable for a wide range of applications.
By combining implants with drug delivery systems the cooperation focuses on increasing the therapeutic efficacy of novel medical technology products. During the production process specific nano-capsules that are filled with active compounds are applied biocompatibility of the implant. Upon implantation the capsules’ contents can be released in a time-lapsed fashion.
"On the basis of the successful developments in recent years many customers prefer to invest in long-term development cooperations with Capsulution,“ said Prof. Edwin Donath, Chairman of the Board of Supervisors of Capsulution NanoScience AG. “This allows us to provide further innovative, specialized and high-qualified products”.
For any further inquiries and information of Capsulution Nanoscience AG, please contact the mentioned contact persons.
